Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kava fatalities in MMWR

This article was originally published in The Tan Sheet

Executive Summary

Possibility of hepatic toxicity associated with use of kava products reported in CDC's Nov. 29 Morbidity & Mortality Weekly Report. MMWR summarizes two case reports: the first involves a 45-year-old woman who underwent liver transplantation after being hospitalized for jaundice and hepatitis following regular use of a kava-containing dietary supplement; the second involves a 14-year-old girl diagnosed with scleral icterus and acute hepatitis following a four-month period of semi-regular kava use. FDA issued a consumer advisory on the botanical earlier this year (1"The Tan Sheet" April 1, 2002)...

You may also be interested in...



Kava AERs not linked to fatalities

Two reports of hepatic toxicity associated with kava and appearing in CDC's Nov. 29 Morbidity & Mortality Weekly Report were not fatalities, as reported in 1"The Tan Sheet" Dec. 2, 2002, p. 6. Patients in both case reports recovered following their illnesses...

Kava Labeling Revisions Adopted By Trade Groups; FDA Issues Advisory

Various dietary supplement trade associations adopted revised kava labeling requirements for their member companies following the release of an 1FDA consumer advisory on the botanical

Trump Pushes Back On OIG Report That Hospitals Want Feds To Better Police Resources, Relax Regs

When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.

Topics

UsernamePublicRestriction

Register

PS094855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel